Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4059 + R-MPV in Untreated PCNSL
NCT06541665Phase 1Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- May 2024
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tirabrutinib in primary central nervous system lymphoma (PCNSL), sponsored by Ono Pharmaceutical. Primary endpoints: Tolerability evaluation at 29 Days and Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) during induction at 2 years. Started May 2024; status: active, not recruiting.
02
Drugs
tirabrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT06541665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06541665.